Sophiris Eyes Another Phase III After Positive BPH Results
This article was originally published in Scrip
Executive Summary
Sophiris Bio Inc. bounced back from a negative interim efficacy report when the company revealed positive results from the Phase III PLUS-1 clinical trial for PRX302 (topsalysin) in the treatment of urinary tract symptoms associated with benign prostatic hyperplasia (BPH), or an enlarged prostate, on Nov. 10.
You may also be interested in...
Patient Death Obscures Efficacy Success For Sophiris’ Intratumoral Prostate Cancer Therapy
The bad outweighed the good for Sophiris on a day in which it unveiled promising Phase IIb data for topsalysin, but also took a huge stock hit with news of a patient death in the trial.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.